International normalized ratio and Model for End-stage Liver Disease score predict short-term outcome in cirrhotic patients after the resolution of hepatic encephalopathy

Table 5 Characteristics of hepatic encephalopathy between survivors and non-survivors at 6 mo n (%)

Variable	Survivors	Non-survivors	P-value
	(n = 179)	(n = 34)
Incentive of HE			0.689
No obvious incentive	92 (51)	22 (65)
High protein diet	40 (22)	7 (21)
Infection	15 (8)	1 (3)
GI bleeding	13 (7)	2 (6)
Electrolyte disturbances	3 (2)	0 (0)
Other	16 (9)	2 (6)
Degree of HE			0.935
I	116 (65)	23 (68)
II	42 (23)	7 (21)
III	18 (10)	3 (9)
IV	3 (1.6)	1 (2.9)
Treatment for HE			0.329
L + AO	116 (65)	23 (68)
L + R + AO	1 (0.6)	0 (0)
L	2 (1.1)	0 (0)
WVE + AO	1 (0.6)	0 (0)
AO	53 (30)	8 (23)
Nothing	1 (0.6)	2 (5.9)
L + AO + WVE	5 (2.8)	1 (2.9)

AO: Aspartate ornithine; GI: Gastrointestinal; HE: Hepatic encephalopathy; L: Lactulose; R: Rifaximin; WVE: White vinegar enema.